Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals

Breast Cancer Clinical Trial

— WIM_22  

Official title:

Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05882578
• Other study ID #: WIM_SURVIVALS_22
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 12, 2023
• Est. completion date: July 31, 2023

Study information

• Verified date: May 2023
• Source: Tigers Running Club
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this interventional study is to analyze the impact of a supervised oncological exercise intervention in surviving breast cancer patients. The main questions it aims to answer are:

• Evaluate the efectivity of a supervised individualized and adapted oncological physical exercise program in the cardiovascular fitness of the participants.

• Analyze the impact of this intervention in the body composition, functionality and quality of life of the parcitipants

Participants will perform a controlled and adapted program, supervised by an especialized professional during 16 weeks.

Researchers will compare this intervention group, where the supervised program will take place, with a control group, where the patients will perform regular physical activity (non-supervised) to see the changes in the efectivity and impact in cardiovascular fitness, body composition and quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 76
• Est. completion date: July 31, 2023
• Est. primary completion date: April 9, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women diagnosed with primary, type I to III A/B cancer, with hormonal positive (ER+ and PG+), triple positive (ER+, PG+ y HER2+) or triple negative subtype.

• Women with chemotherapy and radiotherapy phase complete.

• Women with post-surgery phase complete.

• Women that are within 5 years from diagnostic.

• ECOG Score above or equal to 0 or 1.

Exclusion Criteria:

• Submit medical contraindications to physical exercise by their reference doctor.

• Women in state IV o methastasis.

• Pregnant women.

• Meet any of the criteria of the American Thoracic Society (ATS) to perfrom a cardiovascular fitness test.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Cancer Survivors
• Neoplasms

Intervention

Other:
• Oncological physical exercise intervention
An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested. Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity. Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks. At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.
• Active Physical Activities intervention
An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life. At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.

Locations

Country	Name	City	State
Spain	Tigers Running Club	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
Tigers Running Club

Country where clinical trial is conducted

Spain, 

References & Publications (24)

Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, Fung K, Anderson GM. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. JAMA Cardiol. 2017 Jan 1;2(1):88-93. doi: 10.1001/jamacardio.2016.3841. Erratum In: JAMA Cardiol. 2017 Jul 1;2(7):821. — View Citation

Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004 Aug 1;22(15):3139-48. doi: 10.1200/JCO.2004.09.109. — View Citation

Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016 Apr 1;34(10):1122-30. doi: 10.1200/JCO.2015.64.0409. Epub 2016 Feb 1. — View Citation

Bikiewicz A, Banach M, von Haehling S, Maciejewski M, Bielecka-Dabrowa A. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. ESC Heart Fail. 2021 Aug;8(4):2397-2418. doi: 10.1002/ehf2.13365. Epub 2021 May 5. — View Citation

Bortolozo HI, Derchain S, Vechin FC, Maginador GF, Santos IS, Torresan R, de Nazare Silva Dos Santos P, Sarian LO, Conceicao MS. Aerobic Fitness is a Predictor of Body Composition in Women With Breast Cancer at Diagnosis. Clin Breast Cancer. 2021 Jun;21(3):e245-e251. doi: 10.1016/j.clbc.2020.10.001. Epub 2020 Oct 9. — View Citation

Brubaker P, Jensen A, Jordan J, Lamar Z, Mihalko S, Haykowsky M, Jones L, D Agostino R Jr, Kitzman D, Reding K, Hundley WG. Exercise Capacity Is Reduced in Cancer Survivors Previously Treated With Anthracycline-Based Chemotherapy Despite a Preserved Cardiac Output Response. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2267-2269. doi: 10.1016/j.jcmg.2019.05.016. Epub 2019 Jul 17. No abstract available. — View Citation

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun 2;131(22):1981-8. doi: 10.1161/CIRCULATIONAHA.114.013777. Epub 2015 May 6. — View Citation

Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020 Mar 18;7:26. doi: 10.3389/fcvm.2020.00026. eCollection 2020. — View Citation

Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Fruge AD, Oster RA, Grizzle WE, Norian LA, Yang ES, Della Manna D, Jones LW, Azrad M, Krontiras H. Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics. Int J Cancer. 2020 May 15;146(10):2784-2796. doi: 10.1002/ijc.32637. Epub 2019 Sep 5. — View Citation

Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019;7(1):3-23. doi: 10.2174/2211738507666190122111224. — View Citation

Foulkes SJ, Howden EJ, Bigaran A, Janssens K, Antill Y, Loi S, Claus P, Haykowsky MJ, Daly RM, Fraser SF, LA Gerche A. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. Med Sci Sports Exerc. 2019 Aug;51(8):1573-1581. doi: 10.1249/MSS.0000000000001970. — View Citation

Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, Mahmood SS, Hainer J, Neilan TG, Partridge AH, Di Carli M, Jones LW, Nohria A. Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):315-322. doi: 10.1093/ehjqcco/qcaa015. — View Citation

Hurria A, Jones L, Muss HB. Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions. Am Soc Clin Oncol Educ Book. 2016;35:e516-22. doi: 10.1200/EDBK_156160. — View Citation

Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott JM, Hornsby WE, Coan AD, Herndon JE 2nd, Douglas PS, Haykowsky M. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012 Jul 10;30(20):2530-7. doi: 10.1200/JCO.2011.39.9014. Epub 2012 May 21. — View Citation

Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 2009 Jun;10(6):598-605. doi: 10.1016/S1470-2045(09)70031-2. — View Citation

Kirkham AA, Bland KA, Sayyari S, Campbell KL, Davis MK. Clinically Relevant Physical Benefits of Exercise Interventions in Breast Cancer Survivors. Curr Oncol Rep. 2016 Feb;18(2):12. doi: 10.1007/s11912-015-0496-3. — View Citation

Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002 May 10;277(19):17179-87. doi: 10.1074/jbc.M111604200. Epub 2002 Feb 20. — View Citation

Leclerc AF, Foidart-Dessalle M, Tomasella M, Coucke P, Devos M, Bruyere O, Bury T, Deflandre D, Jerusalem G, Lifrange E, Kaux JF, Crielaard JM, Maquet D. Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. Eur J Phys Rehabil Med. 2017 Oct;53(5):633-642. doi: 10.23736/S1973-9087.17.04551-8. Epub 2017 Mar 20. — View Citation

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229. doi: 10.1124/pr.56.2.6. — View Citation

Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, Favuzzi AMR. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018 Apr;22(7):2175-2185. doi: 10.26355/eurrev_201804_14752. — View Citation

Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc Med. 2020 Jan;30(1):22-28. doi: 10.1016/j.tcm.2019.01.006. Epub 2019 Jan 29. — View Citation

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016 Jan-Feb;66(1):43-73. doi: 10.3322/caac.21319. Epub 2015 Dec 7. — View Citation

Schmidt T, van Mackelenbergh M, Wesch D, Mundhenke C. Physical activity influences the immune system of breast cancer patients. J Cancer Res Ther. 2017 Jul-Sep;13(3):392-398. doi: 10.4103/0973-1482.150356. — View Citation

Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020. — View Citation

* Note: There are 24 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiovascular fitness improvement	Evaluate the effectiveness of the program in the improvement of the cardiovascular capacity in breast cancer survivors (looking for a difference of 3,49 ml/kg/min of oxigen consumption), using a submaximal cardiovascular test.	16 weeks
Secondary	Effects in Body composition	Analyze the effect of the physical exercise program in the body weight, the body mass index (BMI), percentages in body fat, abdominal fat, fat free mass, bone mass and total body water in patinets that surviuve breast cancer via bioimpedancy	16 weeks
Secondary	Physical functionality	Know the impact of the oncologic physical exercise program in the physical functionality of the patients, using the 6 minutes walk test and the 30 seconds sit and stand test.	16 weeks
Secondary	Exercise adherence	Meassure the level of adherence to the oncologic physical exercise program, registering the assistence to te sessions	16 weeks
Secondary	Exercise Level	Evaluate the effect of the intervention in the level of exercise performed by the patients, using the IPAQ cuesttionaire (short version)	16 weeks
Secondary	Fatigue levels	Evaluate the impact of the physical exercise program in the fatigue levels of the participants via the FACT-F questionnaire	16weeks
Secondary	Quality of life and health	Evaluate the impact of the oncologilcal physical exercise program in the quality of life of the patients in relation with their heath, usint the EQ5D questionnaire.	16 weeks
Secondary	Anxiety and depression levels	Evaluate the impact of the physical oncologic program in the anxiety and depression levels of the subjects using the Hospitalary Anxiety and Depression Scale (HADS)	16 weeks

External Links

•   Figures of cancer incidence, prevalence, mortality, survival and risk factors in Spain